Clinical observation of an HIV-infected patient heterozygous for the mutant allele of the CCR5 del 32 chemokine receptor
https://doi.org/10.22625/2072-6732-2021-13-2-159-162
Abstract
The article describes the clinical observation of an HIVinfected patient heterozygous for the mutant allele of the CCR5 del 32 chemokine receptor, who is not receiving antiretroviral therapy. The follow-up showed the course of the disease over 20 years of follow-up, without receiving antiretroviral therapy, with a gradual decrease in the number of CD4-lymphocytes and an increase in viral load.
About the Authors
Z. I. Akhmedjanova
Institute of Immunology and Genomics
Uzbekistan
Uzbekistan
Tashkent
D. M. Urunova
Tashkent Institute for Advanced Training of Physicians
Uzbekistan
Uzbekistan
Tashkent
M. V. Zalyalieva
Institute of Immunology and Genomics
Uzbekistan
Uzbekistan
Tashkent
References
1. VICh-infekcija i SPID: Nacional’noe rukovodstvo / Pod red. V.V. Pokrovskogo. M.: GJeOTAR-Media; 2013.
2. Infekcionnye bolezni: nacional’noe rukovodstvo / Pod red. N. D. Jushhuka, Ju. Ja. Vengerova. 2-e, pererabotannoe i dopolnennoe. M.: GJeOTAR-Media, 2018. 1104 s.
3. Klinicheskij protokol diagnostiki i lechenija VICh-infekcii u vzroslyh. 2017. 31 s.
4. Sluchaj smerti ot cirroza pecheni bol’noj s VICh-infekciej i infil’trativnym tuberkulezom legkih. Babaeva I.Ju., Avdeeva M.G., Shevchenko N.P., Kulagin V.V., Chumachenko G.V., Adamchik N.Ju. Jepidemiol. i infekc. bol. 2013; (1): 49–54.
5. Tuberkulez u VICh-inficirovannyh v Krasnodarskom krae. V kn.: Social’no znachimye i osobo opasnye infekcionnye zabolevanija. Bystrickij D.A., Topol’skaja S.V., Bakulkina O.G., Hasanov H.A., Kulagin V.V., Gorodin V.N., Shevchenko N.P. Materialy III Vserossijskoj nauchno-prakticheskoj konferencii s mezhdunarodnym uchastiem.
6. Fortin E., Heller H. M., Lyons J., Prasad S. Bilateral optic neuritis from acute HIV infection // Neurol Clin Pract. 2019, Jun; 9 (3): e19-e21. DOI: 10.1212/CPJ.0000000000000583.
7. Shilov I.S. Sindrom priobretennogo immunodeficita cheloveka i onkologicheskie zabolevanija. Uspehi sovremennogo estestvoznanija, 2011; (8): 143–144.
8. Fedjaeva O.N. Faktory riska nepriverzhennosti antiretrovirusnoj terapii u bol’nyh VICh-infekciej i sposoby ih vyjavlenija /O.N. Fedjaeva, Sirota H.A. // Medicinskij sovet. Moskva, 2014.-№ 7.-S. 30-33.
9. Reddenna L, Basha SA, Gopal DV, Krishna TR. Highly Active antiretroviral Therapy: Incidence of Adverse Drug Reactions. International Journal of Allied Medicinal Sciences and Clinical Research. 2013 (1): 25–30.
10. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud_Thery F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403–12.
11. Johnston SS, Juday T, Esker S, et al. Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy. Value Health. 2013;16(2):418–425.
12. Juldasheva N.Ju., Zaljalieva M.V, Davidjan M.I., Ruzybakiev RM Rol’ mutacii hemokinovogo receptora CCR5 v razvitii klinicheskoj kartiny SPID. Medicinskaja immunologija, 2001,N 2, c.246.
Review
For citations:
Akhmedjanova Z.I., Urunova D.M., Zalyalieva M.V. Clinical observation of an HIV-infected patient heterozygous for the mutant allele of the CCR5 del 32 chemokine receptor. Journal Infectology. 2021;13(2):159-162. (In Russ.) https://doi.org/10.22625/2072-6732-2021-13-2-159-162
Views:
561
.png)
.png)
Email this article 